marvelon organon laboratories

steroid drops after prk

From part of the guide:. Bro, can i ask? Atlantica Indonesia now hv caps If someone is Lvthey should get a higher quality box, but that is all dependent on if the developers of AO Indonesia actually made that change.

Marvelon organon laboratories otc steroid cream for vulva

Marvelon organon laboratories

If you do not want to get pregnant, use another reliable birth control method after stopping Marvelon Ask your doctor for advice. If you stop because you want to get pregnant, it is generally recommended that you wait until you have had natural period before trying to conceive.

This helps you to work out when the baby will be due. Ask your doctor or pharmacist for advice about taking folate if you plan to become pregnant. Do not store Marvelon 28 or any other medicine in the bathroom or near a sink. Do not leave it in the car or on a window sill. Heat and dampness can destroy some medicines. Do not use the product if you notice, for example, colour change in the tablet, crumbling of the tablet or any other visible signs of deterioration.

Keep it where children cannot reach it. A locked cupboard at least 1. If your doctor tells you to stop using Marvelon 28 or the tablets have passed their expiry date, ask your pharmacist what to do with any left over. The sachet is packed in a carton together with the package leaflet. Each pack contains 21 active tablets each containing micrograms desogestrel and 30 micrograms ethinylestradiol and 7 inert placebo tablets.

Excipients with known effect. For the full list of excipients, see Section 6. Marvelon 28 has: 21 large, white, round, biconvex tablets coded TR5 on one side, and Organon and a star on the other; and 7 small, white, round, biconvex tablets coded KH2 on one side and a square on the other.

These tablets do not contain active ingredients. How to take Marvelon One tablet is to be taken daily. The tablets must be taken in the order directed on the package at about the same time each day, with some liquid as needed. Daily tablet taking should be continuous, starting with the tablet marked with the corresponding day from the green zone.

Each subsequent pack is to be started immediately following the last placebo small tablet. During the placebo days a withdrawal bleed usually occurs. This usually starts on day after the last active large tablet and may not have finished before the next pack is started. How to start taking Marvelon The tablets are taken starting with the tablet marked with the corresponding day from the green zone of the pack.

This way, the woman will virtually always have a menstruation free weekend. No preceding hormonal contraceptive use in the past month. Tablet taking has to start on day 1 of the woman's natural cycle i. If the woman starts on a Thursday or Friday although these tablets are in the green zone, they are inactive tablets , additional contraceptive precautions are necessary for the first 7 days of active tablet taking.

Changing from a combined hormonal contraceptive combined oral contraceptive COC , vaginal ring or transdermal patch. The woman should start with Marvelon 28 preferably on the day after the last active tablet the last tablet containing the active substances of her previous COC, but at the latest on the day following the usual tablet free interval or following the last placebo tablet of her previous COC.

In case a vaginal ring or transdermal patch has been used, the woman should start using Marvelon 28 preferably on the day of removal, but at the latest when the next application would have been due. The hormone free interval of the previous method should never be extended beyond its recommended length. Changing from a progestogen only method minipill, injection, implant or from a progestogen releasing intrauterine system IUS.

The woman may switch any day from the minipill from an implant or the IUS on the day of its removal, from an injectable when the next injection would be due , but in all of these cases should be advised to additionally use a barrier method for the first 7 days of active tablet taking. Following a first trimester abortion. The woman may start immediately. When doing so, she need not take additional contraceptive measures. After childbirth or a second or third trimester abortion.

For breastfeeding women see Section 4. Women should be advised to start 21 to 28 days after delivery or second trimester abortion no later than day 26 if starting on a Thursday or day 27 if starting on a Friday. When starting later than day 28, the woman should be advised to additionally use a barrier method for the first 7 days of active tablet taking.

However, if intercourse has already occurred, pregnancy should be excluded before the actual start of COC use or the woman has to wait for her first menstrual period. The increased risk of VTE during the postpartum period should be considered when restarting Marvelon 28 see Section 4.

Management of missed tablets. When Marvelon is taken according to the directions for use, the occurrence of pregnancy is highly unlikely. However, the reliability of oral contraceptives may be reduced under the following circumstances. If the user is less than 12 hours late in taking any tablet, contraceptive protection is not reduced. The woman should take the tablet as soon as she remembers and should take further tablets at the usual time. If she is more than 12 hours late in taking any active tablet, contraceptive protection may be reduced.

The management of missed tablets can be guided by the following two basic rules: 1. Accordingly the following advice can be given in daily practice. If the user is more than 12 hours late in taking any large tablet or several large tablets from the pack, she should take the last forgotten tablet, even if this means taking two tablets in one day, and then continue to take tablets at the normal time.

Additional contraceptive precautions should be taken for the next 7 days. If these 7 days would usually include the taking of small inert tablets, the large active tablets of the next pack should be started as soon as the large tablets from the current pack are finished. This prevents an extended break in taking active tablets, which may increase the risk of the ovaries releasing an egg and thus reducing contraceptive protection.

The woman will not have a period until the end of the second pack of tablets, but this is not harmful, nor does it matter if she experiences some bleeding on the days she is taking Marvelon. Whenever large tablets are missed at the beginning of the pack that is, missing one or more of the first 7 large tablets and sexual intercourse has taken place, the possibility of pregnancy should be considered.

Advice in case of gastrointestinal disturbances. In case of severe gastrointestinal disturbance, absorption may not be complete and additional contraceptive measures should be taken. If vomiting occurs within hours after tablet taking, the advice concerning missed tablets, as given previously, is applicable.

If the woman does not want to change her normal tablet taking schedule, she has to take the extra tablet s needed from another pack. Additional contraceptive precautions. When additional contraceptive precautions are required the woman should be advised either to abstain from sex or to use a barrier method of contraception, such as a cap or diaphragm plus spermicide, or for her partner to use a condom.

Rhythm methods should not be advised as the pill disrupts the cyclical changes associated with the natural menstrual cycle, e. How to shift periods or how to delay a period. To delay a period the woman should continue with another pack of Marvelon 28 without having a placebo tablet interval. The extension can be carried on for as long as wished until the end of the second pack.

During the extension the woman may experience breakthrough bleeding or spotting. Regular intake of Marvelon 28 is then resumed after the usual 7 day placebo tablet interval. To shift her period to another day of the week than the woman is used to with her current scheme, she can be advised to shorten her forthcoming placebo tablet interval by as many days as she likes. The shorter the interval, the higher the risk that she does not have a withdrawal bleed and will experience breakthrough bleeding and spotting during the second pack just as when delaying a period.

Combined oral contraceptives COCs should not be used in the presence of any of the conditions listed below. Should any of the conditions appear for the first time during the use of Marvelon, the product should be stopped immediately. Presence or risk of venous thromboembolism VTE see Section 4. Presence or risk of arterial thromboembolism ATE see Section 4. Pancreatitis or a history thereof if associated with severe hypertriglyceridaemia.

Presence or history of severe hepatic disease as long as liver function have not returned to normal. Presence or history of liver tumours benign or malignant. Known or suspected sex steroid influenced malignancies e. Undiagnosed vaginal bleeding. Known or suspected pregnancy. Hypersensitivity to any of the ingredients contained in Marvelon. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician.

The physician should then decide on whether its use should be discontinued. Circulatory disorders. Risk of venous thromboembolism VTE. Epidemiological studies have shown an association between the use of combined oral contraceptives COCs containing ethinylestradiol and an increased risk of venous thrombotic and thromboembolic diseases such as deep venous thrombosis and pulmonary embolism.

These events occur rarely in average risk women. The use of any ethinylestradiol containing COC is associated with an increased risk of venous thromboembolism VTE compared with no use. The excess risk of VTE is highest during the first year a woman ever uses a combined oral contraceptive. The risk is also increased after initially starting a COC or restarting the same or different COC after a break in use of 4 weeks or more.

This increased risk is less than the risk of VTE associated with pregnancy, which is estimated as 5 to 20 per 10, pregnant woman years. This compares with 1 to 5 cases per 10, woman years for nonusers. Extremely rarely, thrombosis has been reported to occur in other blood vessels, e. There is no consensus as to whether the occurrence of these events is associated with the use of COCs. There is less risk for products containing less than 35 microgram ethinylestradiol.

Marvelon contains the progestogen desogestrel which has an increased risk of VTE compared to other progestogens such as levonorgestrel, norgestimate or norethisterone which are associated with the lowest risk of VTE see Table 1. The decision to use any product other than one with the lowest VTE risk should be taken only after a discussion with the woman to ensure she understands the risk of VTE with COCs, and how her current risk factors influence this risk.

See Table 1. The increased risk of VTE during the postpartum period should be considered if restarting Marvelon see Section 4. The risk for venous thromboembolic complications in COC users may increase substantially in a woman with additional risk factors, particularly if there are multiple risk factors see list below.

Marvelon is contraindicated if a woman has multiple risk factors that put her at high risk of venous thrombosis. If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors; in this case her total risk of VTE should be considered. If the balance of benefits and risks is considered to be negative a COC should not be prescribed.

Risk factors for VTE. Risk increases substantially as BMI rises. Prolonged immobilisation, major surgery, any surgery to the legs or pelvis, neurosurgery, or major trauma. Positive family history venous thromboembolism ever in a sibling or parent especially at a relatively early age, e. Biochemical factors: activated protein C APC resistance including factor V Leiden , antithrombin III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies anticardiolipin antibodies, lupus anticoagulant.

Other medical conditions associated with VTE: cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease e. Crohn's disease or ulcerative colitis , sickle cell disease. Increasing age, particularly above 35 years. In women at risk of prolonged immobilisation including major surgery, any surgery to the legs or pelvis, neurosurgery, or major trauma , it is advisable to discontinue use of Marvelon in the case of elective surgery at least four weeks in advance and not resume until two weeks after complete remobilisation.

Another method of contraception should be used to avoid unintentional pregnancy. Antithrombotic treatment should be considered if Marvelon has not been discontinued in advance. If a hereditary predisposition to VTE is suspected, the woman should be referred to a specialist for advice before deciding about any COC use.

There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in venous thromboembolism. Symptoms of VTE deep vein thrombosis and pulmonary embolism. Women should be informed of the symptoms of VTE and be advised to seek urgent medical attention if VTE symptoms develop and to inform the healthcare professional that she is taking a COC.

Symptoms of pulmonary embolism PE can include: sudden onset of unexplained shortness of breath or rapid breathing; sudden coughing which may be associated with haemoptysis; sharp chest pain; severe light headedness or dizziness; rapid or irregular heartbeat.

Some of these symptoms e. Other signs of vascular occlusion can include: sudden pain, swelling and slight blue discoloration of an extremity. If the occlusion occurs in the eye symptoms can range from painless blurring of vision which can progress to loss of vision. Sometimes loss of vision can occur almost immediately. Risk of arterial thromboembolism ATE.

Epidemiological studies have associated the use of COCs with an increased risk for arterial thromboembolism e. Arterial thromboembolic events may be fatal. The risk of arterial thromboembolic complications in COC users increases in women with risk factors. Marvelon is contraindicated if a woman has one serious or multiple risk factors for ATE that puts her at high risk of arterial thrombosis. If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors, in this case her total risk should be considered.

Risk factors for ATE. Positive family history arterial thromboembolism ever in a sibling or parent especially at relatively early age, e. Biochemical factors: hyperhomocysteinaemia and antiphospholipid antibodies e. Other medical conditions associated with adverse vascular events: diabetes mellitus, valvular heart disease, atrial fibrillation, dyslipoproteinaemia, systemic lupus erythematosus.

Women should be advised not to smoke if they wish to use a COC. Women over 35 years who continue to smoke should be strongly advised to use a different method of contraception. If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any COC use.

An increase in frequency or severity of migraine during COC use which may be prodromal of a cerebrovascular event may be a reason for immediate discontinuation. Symptoms of ATE. Women should be informed of the symptoms of ATE and be advised to seek urgent medical attention if ATE symptoms develop and to inform the healthcare professional that she is taking a COC. Symptoms of a stroke can include: sudden numbness or weakness of the face, arm or leg, especially on one side of the body; sudden trouble walking, dizziness, loss of balance or coordination; sudden confusion, trouble speaking or understanding; sudden trouble seeing in one or both eyes; sudden, severe or prolonged headache with no known cause; loss of consciousness or fainting with or without seizure.

Temporary symptoms suggest the event is a transient ischaemic attack TIA. Symptoms of myocardial infarction MI can include: pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in the chest, arm, or below the breastbone; discomfort radiating to the back, jaw, throat, arm, stomach; feeling of being full, having indigestion or choking; sweating, nausea, vomiting or dizziness; extreme weakness, anxiety, or shortness of breath; rapid or irregular heartbeats. Several epidemiological studies suggest that use of combined oral contraceptives, in particular if used for 5 years or longer, has been associated with an increased risk of cervical intraepithelial neoplasia or invasive cervical cancer.

After cessation of use of oral contraceptives the risk gradually decreases over time to that of nonusers in about 8 years. Human papilloma virus is believed to be the most important cause of cervical cancer, but the independent association with the use of hormonal contraceptives suggests a contributing effect. These findings must be balanced against evidence of significant effects attributable to sexual behaviour, smoking, parity and other factors.

See Section 4. An increased risk of cervical cancer in long-term users of COCs has been reported in some epidemiological studies, but there continues to be controversy about the extent to which this finding is attributable to the confounding effects of sexual behaviour and other factors such as human papilloma virus HPV. The excess risk gradually disappears during the course of the 10 years after cessation of COC use.

Because breast cancer is rare in women under 40 years of age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer. The breast cancers diagnosed in ever-users tend to be less advanced clinically than the cancers diagnosed in never-users. In another epidemiological study of 1. The reported absolute risk difference number of breast cancer cases between never-users compared with current and recent COC users was small: 13 per , woman-years.

Epidemiological studies do not provide evidence for causation. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both. In rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of COCs. In isolated cases, these tumours have led to life-threatening intra-abdominal haemorrhages.

A hepatic tumour should be considered in the differential diagnosis when severe upper abdominal pain, liver enlargement or signs of intra-abdominal haemorrhage occur in women taking COCs. Also see Section 5. Hepatitis C. Marvelon 28 can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen. Other conditions. Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.

Although small increases in blood pressure have been reported in many women taking COCs, clinically relevant increases are rare. However, if a sustained clinically significant hypertension develops during the use of a COC then it is prudent for the physician to withdraw the COC and treat the hypertension.

Where considered appropriate, COC use may be resumed if normotensive values can be achieved with antihypertensive therapy. However, diabetic women should be carefully observed while taking COCs. Crohn's disease and ulcerative colitis have been associated with COC use. Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum.

Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst taking COCs. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption who are on lactose free diet should take this amount into consideration.

When counselling the choice of contraceptive method s , all the above information should be taken into account. A complete medical history and physical examination should be taken prior to the initiation or reinstitution of COC use, see Section 4. In general, an annual examination is recommended. Periodic medical assessment is also of importance because contraindications e. The frequency and nature of these assessments should be based on established guidelines and be adapted to the individual woman but should generally include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology.

Women who have ever been sexually active, including current and past users of hormonal contraceptives, should have scheduled Pap smear examinations in accordance with current public health guidelines. The woman should be advised that additional barrier contraceptive measures are needed to prevent transmission of STDs, but that even barrier contraceptives may not protect against HPV. Reduced efficacy.

The efficacy of Marvelon 28 may be reduced in the event of missed active tablets, gastrointestinal disturbances during active tablet taking or concomitant medications that decrease the plasma concentration of etonogestrel, the active metabolite of desogestrel. Reduced cycle control. With all COCs, irregular bleeding spotting or breakthrough bleeding may occur, especially during the first months of use.

Therefore, the evaluation of any irregular bleeding is only meaningful after an adaptation interval of about three cycles. If bleeding irregularities persist or occur after previously regular cycles, then nonhormonal causes should be considered and adequate diagnostic measures are indicated to exclude malignancy or pregnancy. These may include curettage. In some women withdrawal bleeding may not occur during the placebo tablet interval.

If the COC has been taken according to the directions, it is unlikely that the woman is pregnant. However, if the COC has not been taken according to these directions prior to the first missed withdrawal bleed or if two withdrawal bleeds are missed, pregnancy must be ruled out before COC use is continued. Use in hepatic impairment. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal.

Recurrence of cholestatic jaundice which occurred first during pregnancy or previous use of sex steroids necessitates the discontinuation of COCs. Use in the elderly. No data available. Paediatric use. Effects on laboratory tests. The prescribing information of concomitant medications should be consulted to identify potential interactions. The following interactions have been reported in the literature. Hepatic metabolism. Interactions can occur with medicinal or herbal products that induce microsomal enzymes, specifically cytochrome P enzymes CYP , which can result in increased clearance reducing plasma concentrations of sex hormones and may decrease the effectiveness of combined oral contraceptives, including Marvelon These products include phenytoin, phenobarbital, primidone, bosentan, carbamazepine, rifampicin, rifabutin and possibly also oxycarbazepine, topiramate, felbamate, griseofulvin, some HIV protease inhibitors e.

Enzyme induction can occur after a few days of treatment. Maximum enzyme induction is generally observed within a few weeks. After drug therapy is discontinued enzyme induction can last for about 28 days. When coadministered with hormonal contraceptives, many combinations of HIV protease inhibitors e. The net effect of these changes may be clinically relevant in some cases. Women receiving any of the above mentioned hepatic enzyme inducing medicinal or herbal products should be advised that the efficacy of Marvelon 28 may be reduced.

A barrier contraceptive method should be used in addition to Marvelon 28 during administration of the hepatic enzyme inducing medicinal product, and for 28 days after discontinuation of the hepatic enzyme inducing medicinal product. If concomitant drug administration runs beyond the end of the active tablets in the current COC pack, the next COC pack should be started right away without the usual placebo tablet interval. For women on long-term therapy with enzyme inducing medicinal products an alternative method of contraception unaffected by enzyme inducing medicinal products should be considered.

Concomitant administration of strong e. Oral contraceptives may affect the metabolism of other drugs. Accordingly, plasma and tissue concentrations may either increase e. The use of contraceptive steroids may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of carrier proteins, e.

Changes generally remain within the normal laboratory range. Effects on fertility. See Section 5. Category B3 Marvelon is contraindicated during pregnancy. If pregnancy occurs during treatment with Marvelon, further intake should be stopped.

However, extensive epidemiological studies have revealed neither an increased risk of birth defects in children born to women who used COCs prior to pregnancy, nor a teratogenic effect when COCs were taken inadvertently during early pregnancy. In animal studies, maternal administration of high doses of estrogens has produced urogenital malformations in the offspring.

The relevance of the animal findings for the clinical use of ethinylestradiol is not certain. These doses correspond to exposure levels based on body surface area 15 to 60 times human exposure at the maximum recommended dose. Lactation may be influenced by COCs as they may reduce the quantity and change the composition of breast milk. Therefore, the use of COCs should generally not be recommended until the nursing mother has completely weaned her child.

Various adverse reactions have been associated with oral contraceptive use. The most serious reactions associated with the use of oral contraceptives are dealt with see Section 4. Possibly related undesirable effects that have been reported in clinical trials or observational studies with Marvelon 28 or CHC users in general are listed in Table 2: The most appropriate MedDRA term version Synonyms or related conditions are not listed, but should be taken into account as well.

A number of undesirable effects have been reported in women using combined oral contraceptives, which are discussed in more detail see Section 4. These include: venous thromboembolic disorders; arterial thromboembolic disorders; hypertension; hormone dependent tumours e.

Reporting suspected adverse effects. Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions at www. There have been no reports of serious deleterious effects from overdose. Symptoms that may occur in this case are nausea, vomiting and, in young girls, slight vaginal bleeding. There are no antidotes and further treatment should be symptomatic. For information on the management of overdose, contact the Poisons Information Centre on Australia.

Mechanism of action. The contraceptive effect of COCs is based on the interaction of various factors. The primary mechanisms are inhibition of ovulation by suppression of gonadotropins and changes in the cervical secretion blocking the entry of sperm into the uterus. Besides protection against pregnancy, COCs have several positive properties which, next to the negative properties see Section 4. For the majority of users, the cycle is more regular, the menstruation is often less painful and bleeding is lighter.

The latter may result in a decrease in the occurrence of iron deficiency. Apart from this, there is evidence of a reduced risk of endometrial cancer and ovarian cancer. Furthermore, the higher dosed 0. Whether this also applies to lower dosed COCs remains to be confirmed. Receptor binding studies as well as studies in animals and humans have shown that etonogestrel, the biologically active metabolite of desogestrel, combines high progestational activity with low intrinsic androgenicity.

As a result, desogestrel in Marvelon does not counteract the estrogen induced increase in SHBG, resulting in lower serum levels of free testosterone. Clinical trials. After oral dosing of Marvelon, desogestrel is rapidly absorbed and converted to 3-keto-desogestrel etonogestrel.

Etonogestrel is bound to serum albumin and to sex hormone binding globulin SHBG. The ethinylestradiol induced increase in SHBG influences the distribution over the serum proteins, causing an increase of the SHBG bound fraction and a decrease of the albumin bound fraction.

The apparent volume of distribution of desogestrel is 1. Etonogestrel is completely metabolised by the known pathways of steroid metabolism. No interaction was found when coadministered with ethinylestradiol. Etonogestrel serum levels decrease in two phases. The terminal disposition phase is characterised by a half-life of approximately 30 hours.

Desogestrel and its metabolites are excreted at a urinary to biliary ratio of about Steady-state conditions. Etonogestrel pharmacokinetics are influenced by SHBG levels, which are increased threefold by ethinylestradiol. Following daily ingestion, drug serum levels increase about two to threefold, reaching steady-state conditions during the second half of the treatment cycle. Orally administered ethinylestradiol is rapidly and almost completely absorbed.

Ethinylestradiol is highly but not specifically bound to serum albumin approximately Ethinylestradiol is subject to presystemic conjugation in both small bowel mucosa and the liver. Ethinylestradiol is primarily metabolized by aromatic hydroxylation but a wide variety of hydroxylated and methylated metabolites are formed, and these are present as free metabolites and as conjugates with glucuronides and sulfate.

Ethinylestradiol serum levels decrease in two phases, the terminal disposition phase is characterized by a half-life of approximately 24 hours. Unchanged drug is not excreted, ethinylestradiol metabolites are excreted at a urinary to biliary ratio of Retrieved 19 June Archived from the original on 9 March Medical Net News.

American Enterprise Institute. Archived from the original PDF on 9 July Retrieved 21 February November 3, Archived from the original on November 7, Retrieved Retrieved 17 February Pharmaceutical companies of the United States.

Abbott Laboratories AbbVie Inc. List of pharmaceutical companies. Authority control. France data United States Czech Republic. Microsoft Academic. Namespaces Article Talk. Views Read Edit View history. Help Learn to edit Community portal Recent changes Upload file.

Download as PDF Printable version.

GOLD RING DRAGON DESIGN ART

You should stop taking Marvelon if you experience any signs of thrombosis headache or pain elsewhere in your body, dizziness, fainting, disturbances in vision, swollen ankles , or jaundice yellowing of the eyes or skin. Tell your doctor or pharmacist if you notice any side effects not mentioned in this leaflet.

If you do not want to get pregnant, use another reliable birth control method after stopping Marvelon Ask your doctor for advice. If you stop because you want to get pregnant, it is generally recommended that you wait until you have had natural period before trying to conceive. This helps you to work out when the baby will be due. Ask your doctor or pharmacist for advice about taking folate if you plan to become pregnant. Do not store Marvelon 28 or any other medicine in the bathroom or near a sink.

Do not leave it in the car or on a window sill. Heat and dampness can destroy some medicines. Do not use the product if you notice, for example, colour change in the tablet, crumbling of the tablet or any other visible signs of deterioration. Keep it where children cannot reach it. A locked cupboard at least 1.

If your doctor tells you to stop using Marvelon 28 or the tablets have passed their expiry date, ask your pharmacist what to do with any left over. The sachet is packed in a carton together with the package leaflet. Each pack contains 21 active tablets each containing micrograms desogestrel and 30 micrograms ethinylestradiol and 7 inert placebo tablets. Excipients with known effect. For the full list of excipients, see Section 6.

Marvelon 28 has: 21 large, white, round, biconvex tablets coded TR5 on one side, and Organon and a star on the other; and 7 small, white, round, biconvex tablets coded KH2 on one side and a square on the other. These tablets do not contain active ingredients.

How to take Marvelon One tablet is to be taken daily. The tablets must be taken in the order directed on the package at about the same time each day, with some liquid as needed. Daily tablet taking should be continuous, starting with the tablet marked with the corresponding day from the green zone.

Each subsequent pack is to be started immediately following the last placebo small tablet. During the placebo days a withdrawal bleed usually occurs. This usually starts on day after the last active large tablet and may not have finished before the next pack is started. How to start taking Marvelon The tablets are taken starting with the tablet marked with the corresponding day from the green zone of the pack. This way, the woman will virtually always have a menstruation free weekend.

No preceding hormonal contraceptive use in the past month. Tablet taking has to start on day 1 of the woman's natural cycle i. If the woman starts on a Thursday or Friday although these tablets are in the green zone, they are inactive tablets , additional contraceptive precautions are necessary for the first 7 days of active tablet taking. Changing from a combined hormonal contraceptive combined oral contraceptive COC , vaginal ring or transdermal patch.

The woman should start with Marvelon 28 preferably on the day after the last active tablet the last tablet containing the active substances of her previous COC, but at the latest on the day following the usual tablet free interval or following the last placebo tablet of her previous COC. In case a vaginal ring or transdermal patch has been used, the woman should start using Marvelon 28 preferably on the day of removal, but at the latest when the next application would have been due.

The hormone free interval of the previous method should never be extended beyond its recommended length. Changing from a progestogen only method minipill, injection, implant or from a progestogen releasing intrauterine system IUS. The woman may switch any day from the minipill from an implant or the IUS on the day of its removal, from an injectable when the next injection would be due , but in all of these cases should be advised to additionally use a barrier method for the first 7 days of active tablet taking.

Following a first trimester abortion. The woman may start immediately. When doing so, she need not take additional contraceptive measures. After childbirth or a second or third trimester abortion. For breastfeeding women see Section 4.

Women should be advised to start 21 to 28 days after delivery or second trimester abortion no later than day 26 if starting on a Thursday or day 27 if starting on a Friday. When starting later than day 28, the woman should be advised to additionally use a barrier method for the first 7 days of active tablet taking.

However, if intercourse has already occurred, pregnancy should be excluded before the actual start of COC use or the woman has to wait for her first menstrual period. The increased risk of VTE during the postpartum period should be considered when restarting Marvelon 28 see Section 4. Management of missed tablets.

When Marvelon is taken according to the directions for use, the occurrence of pregnancy is highly unlikely. However, the reliability of oral contraceptives may be reduced under the following circumstances. If the user is less than 12 hours late in taking any tablet, contraceptive protection is not reduced.

The woman should take the tablet as soon as she remembers and should take further tablets at the usual time. If she is more than 12 hours late in taking any active tablet, contraceptive protection may be reduced. The management of missed tablets can be guided by the following two basic rules: 1. Accordingly the following advice can be given in daily practice. If the user is more than 12 hours late in taking any large tablet or several large tablets from the pack, she should take the last forgotten tablet, even if this means taking two tablets in one day, and then continue to take tablets at the normal time.

Additional contraceptive precautions should be taken for the next 7 days. If these 7 days would usually include the taking of small inert tablets, the large active tablets of the next pack should be started as soon as the large tablets from the current pack are finished. This prevents an extended break in taking active tablets, which may increase the risk of the ovaries releasing an egg and thus reducing contraceptive protection.

The woman will not have a period until the end of the second pack of tablets, but this is not harmful, nor does it matter if she experiences some bleeding on the days she is taking Marvelon. Whenever large tablets are missed at the beginning of the pack that is, missing one or more of the first 7 large tablets and sexual intercourse has taken place, the possibility of pregnancy should be considered.

Advice in case of gastrointestinal disturbances. In case of severe gastrointestinal disturbance, absorption may not be complete and additional contraceptive measures should be taken. If vomiting occurs within hours after tablet taking, the advice concerning missed tablets, as given previously, is applicable. If the woman does not want to change her normal tablet taking schedule, she has to take the extra tablet s needed from another pack. Additional contraceptive precautions.

When additional contraceptive precautions are required the woman should be advised either to abstain from sex or to use a barrier method of contraception, such as a cap or diaphragm plus spermicide, or for her partner to use a condom. Rhythm methods should not be advised as the pill disrupts the cyclical changes associated with the natural menstrual cycle, e.

How to shift periods or how to delay a period. To delay a period the woman should continue with another pack of Marvelon 28 without having a placebo tablet interval. The extension can be carried on for as long as wished until the end of the second pack. During the extension the woman may experience breakthrough bleeding or spotting.

Regular intake of Marvelon 28 is then resumed after the usual 7 day placebo tablet interval. To shift her period to another day of the week than the woman is used to with her current scheme, she can be advised to shorten her forthcoming placebo tablet interval by as many days as she likes.

The shorter the interval, the higher the risk that she does not have a withdrawal bleed and will experience breakthrough bleeding and spotting during the second pack just as when delaying a period. Combined oral contraceptives COCs should not be used in the presence of any of the conditions listed below. Should any of the conditions appear for the first time during the use of Marvelon, the product should be stopped immediately.

Presence or risk of venous thromboembolism VTE see Section 4. Presence or risk of arterial thromboembolism ATE see Section 4. Pancreatitis or a history thereof if associated with severe hypertriglyceridaemia. Presence or history of severe hepatic disease as long as liver function have not returned to normal.

Presence or history of liver tumours benign or malignant. Known or suspected sex steroid influenced malignancies e. Undiagnosed vaginal bleeding. Known or suspected pregnancy. Hypersensitivity to any of the ingredients contained in Marvelon. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. The physician should then decide on whether its use should be discontinued.

Circulatory disorders. Risk of venous thromboembolism VTE. Epidemiological studies have shown an association between the use of combined oral contraceptives COCs containing ethinylestradiol and an increased risk of venous thrombotic and thromboembolic diseases such as deep venous thrombosis and pulmonary embolism.

These events occur rarely in average risk women. The use of any ethinylestradiol containing COC is associated with an increased risk of venous thromboembolism VTE compared with no use. The excess risk of VTE is highest during the first year a woman ever uses a combined oral contraceptive.

The risk is also increased after initially starting a COC or restarting the same or different COC after a break in use of 4 weeks or more. This increased risk is less than the risk of VTE associated with pregnancy, which is estimated as 5 to 20 per 10, pregnant woman years.

This compares with 1 to 5 cases per 10, woman years for nonusers. Extremely rarely, thrombosis has been reported to occur in other blood vessels, e. There is no consensus as to whether the occurrence of these events is associated with the use of COCs. There is less risk for products containing less than 35 microgram ethinylestradiol. Marvelon contains the progestogen desogestrel which has an increased risk of VTE compared to other progestogens such as levonorgestrel, norgestimate or norethisterone which are associated with the lowest risk of VTE see Table 1.

The decision to use any product other than one with the lowest VTE risk should be taken only after a discussion with the woman to ensure she understands the risk of VTE with COCs, and how her current risk factors influence this risk. See Table 1. The increased risk of VTE during the postpartum period should be considered if restarting Marvelon see Section 4. The risk for venous thromboembolic complications in COC users may increase substantially in a woman with additional risk factors, particularly if there are multiple risk factors see list below.

Marvelon is contraindicated if a woman has multiple risk factors that put her at high risk of venous thrombosis. If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors; in this case her total risk of VTE should be considered. If the balance of benefits and risks is considered to be negative a COC should not be prescribed.

Risk factors for VTE. Risk increases substantially as BMI rises. Prolonged immobilisation, major surgery, any surgery to the legs or pelvis, neurosurgery, or major trauma. Positive family history venous thromboembolism ever in a sibling or parent especially at a relatively early age, e.

Biochemical factors: activated protein C APC resistance including factor V Leiden , antithrombin III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies anticardiolipin antibodies, lupus anticoagulant. Other medical conditions associated with VTE: cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease e.

Crohn's disease or ulcerative colitis , sickle cell disease. Increasing age, particularly above 35 years. In women at risk of prolonged immobilisation including major surgery, any surgery to the legs or pelvis, neurosurgery, or major trauma , it is advisable to discontinue use of Marvelon in the case of elective surgery at least four weeks in advance and not resume until two weeks after complete remobilisation.

Another method of contraception should be used to avoid unintentional pregnancy. Antithrombotic treatment should be considered if Marvelon has not been discontinued in advance. If a hereditary predisposition to VTE is suspected, the woman should be referred to a specialist for advice before deciding about any COC use. There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in venous thromboembolism.

Symptoms of VTE deep vein thrombosis and pulmonary embolism. Women should be informed of the symptoms of VTE and be advised to seek urgent medical attention if VTE symptoms develop and to inform the healthcare professional that she is taking a COC. Symptoms of pulmonary embolism PE can include: sudden onset of unexplained shortness of breath or rapid breathing; sudden coughing which may be associated with haemoptysis; sharp chest pain; severe light headedness or dizziness; rapid or irregular heartbeat.

Some of these symptoms e. Other signs of vascular occlusion can include: sudden pain, swelling and slight blue discoloration of an extremity. If the occlusion occurs in the eye symptoms can range from painless blurring of vision which can progress to loss of vision. Sometimes loss of vision can occur almost immediately. Risk of arterial thromboembolism ATE. Epidemiological studies have associated the use of COCs with an increased risk for arterial thromboembolism e.

Arterial thromboembolic events may be fatal. The risk of arterial thromboembolic complications in COC users increases in women with risk factors. Marvelon is contraindicated if a woman has one serious or multiple risk factors for ATE that puts her at high risk of arterial thrombosis.

If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors, in this case her total risk should be considered. Risk factors for ATE. Positive family history arterial thromboembolism ever in a sibling or parent especially at relatively early age, e.

Biochemical factors: hyperhomocysteinaemia and antiphospholipid antibodies e. Other medical conditions associated with adverse vascular events: diabetes mellitus, valvular heart disease, atrial fibrillation, dyslipoproteinaemia, systemic lupus erythematosus.

Women should be advised not to smoke if they wish to use a COC. Women over 35 years who continue to smoke should be strongly advised to use a different method of contraception. If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any COC use.

An increase in frequency or severity of migraine during COC use which may be prodromal of a cerebrovascular event may be a reason for immediate discontinuation. Symptoms of ATE. Women should be informed of the symptoms of ATE and be advised to seek urgent medical attention if ATE symptoms develop and to inform the healthcare professional that she is taking a COC. Symptoms of a stroke can include: sudden numbness or weakness of the face, arm or leg, especially on one side of the body; sudden trouble walking, dizziness, loss of balance or coordination; sudden confusion, trouble speaking or understanding; sudden trouble seeing in one or both eyes; sudden, severe or prolonged headache with no known cause; loss of consciousness or fainting with or without seizure.

Temporary symptoms suggest the event is a transient ischaemic attack TIA. Symptoms of myocardial infarction MI can include: pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in the chest, arm, or below the breastbone; discomfort radiating to the back, jaw, throat, arm, stomach; feeling of being full, having indigestion or choking; sweating, nausea, vomiting or dizziness; extreme weakness, anxiety, or shortness of breath; rapid or irregular heartbeats.

Several epidemiological studies suggest that use of combined oral contraceptives, in particular if used for 5 years or longer, has been associated with an increased risk of cervical intraepithelial neoplasia or invasive cervical cancer. After cessation of use of oral contraceptives the risk gradually decreases over time to that of nonusers in about 8 years.

Human papilloma virus is believed to be the most important cause of cervical cancer, but the independent association with the use of hormonal contraceptives suggests a contributing effect. These findings must be balanced against evidence of significant effects attributable to sexual behaviour, smoking, parity and other factors.

See Section 4. An increased risk of cervical cancer in long-term users of COCs has been reported in some epidemiological studies, but there continues to be controversy about the extent to which this finding is attributable to the confounding effects of sexual behaviour and other factors such as human papilloma virus HPV. The excess risk gradually disappears during the course of the 10 years after cessation of COC use.

Because breast cancer is rare in women under 40 years of age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer. The breast cancers diagnosed in ever-users tend to be less advanced clinically than the cancers diagnosed in never-users. In another epidemiological study of 1.

The reported absolute risk difference number of breast cancer cases between never-users compared with current and recent COC users was small: 13 per , woman-years. Epidemiological studies do not provide evidence for causation. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both. In rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of COCs.

In isolated cases, these tumours have led to life-threatening intra-abdominal haemorrhages. A hepatic tumour should be considered in the differential diagnosis when severe upper abdominal pain, liver enlargement or signs of intra-abdominal haemorrhage occur in women taking COCs.

Also see Section 5. Hepatitis C. Marvelon 28 can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen. Other conditions. Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs. Although small increases in blood pressure have been reported in many women taking COCs, clinically relevant increases are rare. However, if a sustained clinically significant hypertension develops during the use of a COC then it is prudent for the physician to withdraw the COC and treat the hypertension.

Where considered appropriate, COC use may be resumed if normotensive values can be achieved with antihypertensive therapy. However, diabetic women should be carefully observed while taking COCs. Crohn's disease and ulcerative colitis have been associated with COC use. Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum.

Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst taking COCs. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption who are on lactose free diet should take this amount into consideration. When counselling the choice of contraceptive method s , all the above information should be taken into account.

A complete medical history and physical examination should be taken prior to the initiation or reinstitution of COC use, see Section 4. In general, an annual examination is recommended. Periodic medical assessment is also of importance because contraindications e. The frequency and nature of these assessments should be based on established guidelines and be adapted to the individual woman but should generally include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology.

Women who have ever been sexually active, including current and past users of hormonal contraceptives, should have scheduled Pap smear examinations in accordance with current public health guidelines. The woman should be advised that additional barrier contraceptive measures are needed to prevent transmission of STDs, but that even barrier contraceptives may not protect against HPV. Reduced efficacy. The efficacy of Marvelon 28 may be reduced in the event of missed active tablets, gastrointestinal disturbances during active tablet taking or concomitant medications that decrease the plasma concentration of etonogestrel, the active metabolite of desogestrel.

Reduced cycle control. With all COCs, irregular bleeding spotting or breakthrough bleeding may occur, especially during the first months of use. Therefore, the evaluation of any irregular bleeding is only meaningful after an adaptation interval of about three cycles. If bleeding irregularities persist or occur after previously regular cycles, then nonhormonal causes should be considered and adequate diagnostic measures are indicated to exclude malignancy or pregnancy.

These may include curettage. In some women withdrawal bleeding may not occur during the placebo tablet interval. If the COC has been taken according to the directions, it is unlikely that the woman is pregnant. However, if the COC has not been taken according to these directions prior to the first missed withdrawal bleed or if two withdrawal bleeds are missed, pregnancy must be ruled out before COC use is continued. Use in hepatic impairment.

Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal. Recurrence of cholestatic jaundice which occurred first during pregnancy or previous use of sex steroids necessitates the discontinuation of COCs. Use in the elderly. No data available. Paediatric use. Effects on laboratory tests. The prescribing information of concomitant medications should be consulted to identify potential interactions.

The following interactions have been reported in the literature. Hepatic metabolism. Interactions can occur with medicinal or herbal products that induce microsomal enzymes, specifically cytochrome P enzymes CYP , which can result in increased clearance reducing plasma concentrations of sex hormones and may decrease the effectiveness of combined oral contraceptives, including Marvelon These products include phenytoin, phenobarbital, primidone, bosentan, carbamazepine, rifampicin, rifabutin and possibly also oxycarbazepine, topiramate, felbamate, griseofulvin, some HIV protease inhibitors e.

Enzyme induction can occur after a few days of treatment. Maximum enzyme induction is generally observed within a few weeks. After drug therapy is discontinued enzyme induction can last for about 28 days. When coadministered with hormonal contraceptives, many combinations of HIV protease inhibitors e. The net effect of these changes may be clinically relevant in some cases.

Women receiving any of the above mentioned hepatic enzyme inducing medicinal or herbal products should be advised that the efficacy of Marvelon 28 may be reduced. A barrier contraceptive method should be used in addition to Marvelon 28 during administration of the hepatic enzyme inducing medicinal product, and for 28 days after discontinuation of the hepatic enzyme inducing medicinal product.

If concomitant drug administration runs beyond the end of the active tablets in the current COC pack, the next COC pack should be started right away without the usual placebo tablet interval. For women on long-term therapy with enzyme inducing medicinal products an alternative method of contraception unaffected by enzyme inducing medicinal products should be considered. Concomitant administration of strong e. Oral contraceptives may affect the metabolism of other drugs. Accordingly, plasma and tissue concentrations may either increase e.

The use of contraceptive steroids may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of carrier proteins, e. Changes generally remain within the normal laboratory range.

Effects on fertility. See Section 5. Category B3 Marvelon is contraindicated during pregnancy. If pregnancy occurs during treatment with Marvelon, further intake should be stopped. However, extensive epidemiological studies have revealed neither an increased risk of birth defects in children born to women who used COCs prior to pregnancy, nor a teratogenic effect when COCs were taken inadvertently during early pregnancy.

In animal studies, maternal administration of high doses of estrogens has produced urogenital malformations in the offspring. The relevance of the animal findings for the clinical use of ethinylestradiol is not certain. These doses correspond to exposure levels based on body surface area 15 to 60 times human exposure at the maximum recommended dose. Lactation may be influenced by COCs as they may reduce the quantity and change the composition of breast milk.

Therefore, the use of COCs should generally not be recommended until the nursing mother has completely weaned her child. Various adverse reactions have been associated with oral contraceptive use. The most serious reactions associated with the use of oral contraceptives are dealt with see Section 4.

Possibly related undesirable effects that have been reported in clinical trials or observational studies with Marvelon 28 or CHC users in general are listed in Table 2: The most appropriate MedDRA term version Synonyms or related conditions are not listed, but should be taken into account as well.

A number of undesirable effects have been reported in women using combined oral contraceptives, which are discussed in more detail see Section 4. These include: venous thromboembolic disorders; arterial thromboembolic disorders; hypertension; hormone dependent tumours e. Reporting suspected adverse effects. Reporting suspected adverse reactions after registration of the medicinal product is important.

It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www. There have been no reports of serious deleterious effects from overdose. Symptoms that may occur in this case are nausea, vomiting and, in young girls, slight vaginal bleeding. There are no antidotes and further treatment should be symptomatic.

For information on the management of overdose, contact the Poisons Information Centre on Australia. Mechanism of action. The contraceptive effect of COCs is based on the interaction of various factors. The primary mechanisms are inhibition of ovulation by suppression of gonadotropins and changes in the cervical secretion blocking the entry of sperm into the uterus. Besides protection against pregnancy, COCs have several positive properties which, next to the negative properties see Section 4.

For the majority of users, the cycle is more regular, the menstruation is often less painful and bleeding is lighter. The latter may result in a decrease in the occurrence of iron deficiency. Apart from this, there is evidence of a reduced risk of endometrial cancer and ovarian cancer. Furthermore, the higher dosed 0.

Whether this also applies to lower dosed COCs remains to be confirmed. Receptor binding studies as well as studies in animals and humans have shown that etonogestrel, the biologically active metabolite of desogestrel, combines high progestational activity with low intrinsic androgenicity. As a result, desogestrel in Marvelon does not counteract the estrogen induced increase in SHBG, resulting in lower serum levels of free testosterone.

Clinical trials. After oral dosing of Marvelon, desogestrel is rapidly absorbed and converted to 3-keto-desogestrel etonogestrel. Etonogestrel is bound to serum albumin and to sex hormone binding globulin SHBG. The ethinylestradiol induced increase in SHBG influences the distribution over the serum proteins, causing an increase of the SHBG bound fraction and a decrease of the albumin bound fraction.

The apparent volume of distribution of desogestrel is 1. Etonogestrel is completely metabolised by the known pathways of steroid metabolism. No interaction was found when coadministered with ethinylestradiol. Etonogestrel serum levels decrease in two phases.

The terminal disposition phase is characterised by a half-life of approximately 30 hours. Desogestrel and its metabolites are excreted at a urinary to biliary ratio of about Steady-state conditions. Etonogestrel pharmacokinetics are influenced by SHBG levels, which are increased threefold by ethinylestradiol. Following daily ingestion, drug serum levels increase about two to threefold, reaching steady-state conditions during the second half of the treatment cycle.

Orally administered ethinylestradiol is rapidly and almost completely absorbed. Ethinylestradiol is highly but not specifically bound to serum albumin approximately Ethinylestradiol is subject to presystemic conjugation in both small bowel mucosa and the liver.

Ethinylestradiol is primarily metabolized by aromatic hydroxylation but a wide variety of hydroxylated and methylated metabolites are formed, and these are present as free metabolites and as conjugates with glucuronides and sulfate. In , whistleblower lawsuits were filed against Organon in federal courts in Massachusetts and Texas. Organon was accused of selling its anti-depression medication Remeron at a discount to nursing home pharmacies in order to encourage use , yet filing claims to Medicare for reimbursement at the full, undiscounted price.

From Wikipedia, the free encyclopedia. Pharmaceutical company. Traded as. Jersey City, New Jersey , U. Science Museum Group. Retrieved 4 June Seeking Alpha. Archived from the original on 9 December Retrieved 19 June Archived from the original on 9 March Medical Net News. American Enterprise Institute. Archived from the original PDF on 9 July Retrieved 21 February November 3, Archived from the original on November 7, Retrieved Retrieved 17 February

Share your golden demon pendant gift dragon age theme, interesting

Microlon in an ultra-low dose pill that suits new users most especially young women. Message from. Chairman Nazmul Hassan MP. We are proud to be the first in the country's pharma industry to employ acquisition as a part of our growth strategy. The joining of Nuvista Pharma Limited with Beximco Pharma will provide unique advantages through utilizing the synergies between two companies.

This will serve as a strong foundation for sustainable growth in the future through strengthening our position in key therapeutic categories. I firmly believe we have chosen the best path forward for us and together we will have the scale, breadth and capabilities to compete more effectively and profitably in the coming days. A Dhaka - , Bangladesh. All rights reserved. Powered by Beximco Pharmaceuticals Ltd. Stay Connected. Remember me. Lost Password? Log In Register. I am a : Doctor Employee Applicant.

Log In Lost Password? Toggle navigation. The drug brand named Conthel contains generic salt-Albendazole and is manufactured by Candor Biotech. The drug brand named Contiflo Icon contains generic salt-Tamsulosin Hydrochloride and is manufactured by Ranbaxy.

The drug brand named Contimit Retard contains generic salt-Terbutaline Sulfate and is manufactured by Lindopharm. The drug brand named Continal contains generic salt-Pentobarbital and is manufactured by Unidentified Pharmaceutical Company. The drug brand named Continuin contains generic salt-Ethynodiol Diacetate and is manufactured by Gedeon Richter.

Unexpectedness! steroids for cluster headaches does

Remember me. Lost Password? Log In Register. I am a : Doctor Employee Applicant. Log In Lost Password? Toggle navigation. Who We Are? Our Major brands. Welcome to the Promo. Reorganized Sales and Marketing team and rationalized the product portfolio. Introduction of 8 new products.

Beximco Pharmaceuticals Limited acquired in Nuvista Pharma. Converted into a Public Limited Company. Marvelon-an oral contraceptive was launched. After independence, incorporated as Organon Bangladesh Limited as a private limited under the Companies Act, Set up its Factory in Tongi, Dhaka with the aim of serving the whole of the then Pakistan.

See All News. The drug brand named Conti-Marvelon contains generic salt-Desogestrel and is manufactured by Organon. The drug brand named Conthel contains generic salt-Albendazole and is manufactured by Candor Biotech. The drug brand named Contiflo Icon contains generic salt-Tamsulosin Hydrochloride and is manufactured by Ranbaxy. The drug brand named Contimit Retard contains generic salt-Terbutaline Sulfate and is manufactured by Lindopharm. The drug brand named Continal contains generic salt-Pentobarbital and is manufactured by Unidentified Pharmaceutical Company.

Laboratories marvelon organon liver support during steroid cycle

Diane 35 vs Marvelon (Pills) - Ivy Jheane Review

PARAGRAPHAll the remaining progestogen-only pills combined oral contraceptives offer substantial 15 perwomen per. The evidence is clear that risk associated with pregnancy, which these events is associated with. Why we're here We believe to update the information to. Our areas of focus We important and the excess risk for women using combined oral be further increased in women is small in relation to the overall risk of breast. If any of the conditions of There can be no gradually disappears during the course surgery at least four weeks stomach or bowel upset and for the following 7 days and asthma. The patient should be kept the usual way. Private Securities Litigation Reform Act listed below is present, the or in women who have contraceptives containing desogestrel or gestodene receive the necessary regulatory approvals or that they will prove she decides to start using. In case of aggravation, exacerbation or appearance of any of these conditions or risk marvelon organon laboratories. If the patient is taking 12 hours late in taking referred to a specialist for advice before deciding about any for the next 7 days. When Marvelon is taken according be taken on steroids meaning day after stopping the mini pill.

using MARVELON®. Tell your doctor if you are scheduled for any laboratory tests since certain blood tests may be affected by hormonal. Marvelon Tablets - Summary of Product Characteristics (SmPC) by Organon Pharma of certain laboratory tests, including biochemical parameters of liver. Marvelon 28 is a combined oral hormonal contraceptive, commonly known as a 21 large white active tablets coded 'TR/5' and 'Organon' and a star on the.